SCHEDULE 13G/A: Galaxy Group Entities Reduce Stake in ATAI Life Sciences to 4.2%

Sentiment:

Beneficial Ownership Update 27 May 2025 8:14 PM

Galaxy Group Funding ECI U LLC, Galaxy Group Investments LLC, and Michael E. Novogratz have collectively reduced their beneficial ownership in ATAI Life Sciences N.V. to 4.2% of common shares.

Worse than expectedThe beneficial ownership of Galaxy Group entities and Michael E. Novogratz in ATAI Life Sciences N.V. has decreased to 4.2%, falling below the 5% threshold. This reduction suggests a divestment or decreased conviction from a notable investor, which is generally perceived negatively by the market.

Summary

The filing is an Amendment No. 1 to a Schedule 13G, indicating a change in beneficial ownership.
The reporting persons are Galaxy Group Funding ECI U LLC, Galaxy Group Investments LLC, and Michael E. Novogratz.
As of March 31, 2025, the reporting persons collectively beneficially own 8,471,736 common shares of ATAI Life Sciences N.V.
This ownership represents 4.2% of the total class of common shares.
The reporting persons hold shared voting power and shared dispositive power over all 8,471,736 shares.

Sentiment

Score: 3

Explanation: The filing indicates a reduction in beneficial ownership by Galaxy Group entities and Michael E. Novogratz to 4.2%, suggesting a divestment or decreased confidence from a notable investor, which is generally perceived negatively by the market.

Negatives

Galaxy Group entities and Michael E. Novogratz have reduced their beneficial ownership in ATAI Life Sciences N.V. to 4.2% of the common shares, falling below the 5% threshold. This reduction suggests a divestment or decreased conviction by a significant investor.

Risks

A notable investor group reducing its stake below 5% could signal a loss of confidence in ATAI Life Sciences' future prospects or a shift in investment strategy, potentially leading to negative market perception and increased selling pressure on the stock.

Future Outlook

Industry Context

In the life sciences and biotechnology sector, investor confidence is a critical driver of valuation. A reduction in stake by a significant investor, such as the Galaxy Group entities and Michael E. Novogratz, can be interpreted by the market as a negative signal regarding the company's near-term prospects or long-term strategy, potentially impacting investor sentiment across the sector, especially for companies in similar developmental stages.

Stakeholder Impact

Shareholders: May interpret the reduction in stake by a significant investor as a negative signal, potentially leading to decreased share price or investor confidence.

Key Dates

Date	Description
03/31/2025	Date of event which requires filing of this statement (beneficial ownership change).
05/27/2025	Date of filing of this Schedule 13G Amendment No. 1.

Recommendation

sell

Keywords

ATAI Life Sciences, Galaxy Group, Michael E. Novogratz, Schedule 13G, beneficial ownership, stake reduction, common shares, biotechnology, pharmaceuticals

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.